Zydus And Lupin Join Hands To Co Market Treatment

Top Stories

Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

Stock chart

Zydus and Lupin join hands to Co-market treatment

ri-calendar-2-lineNov 3, 2023

By: BlinkX Research Team

FbkFbkTwitterTelegram

Zydus Lifesciences Limited and Lupin Limited have entered a licensing and supply agreement to co-market Saroglitazar Mg, designed for the treatment of Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steato Hepatitis (NASH) in India. Saroglitazar Mg offers enhanced compliance with its once daily 4mg dose, reducing pill burden and providing patients with greater convenience.


Under the agreement, Lupin gains semi-exclusive rights to co-market the product in India under the brand name LINVAS. Zydus will continue marketing the drug under the brand names Lipaglyn and Bilypsa. Lupin will make upfront licensing fees and milestone payments to Zydus based on predefined achievements.


In India, NAFLD is not confined to obese or Diabetes Mellitus patients; it can also develop independently of obesity, termed "lean" NAFLD. The prevalence of NAFLD/NASH has risen due to increased obesity and other lifestyle-related conditions.


Dr. Sharvil Patel, Managing Director of Zydus Lifesciences Ltd., noted that Saroglitazar Mg has substantially improved patients' quality of life. Nilesh Gupta, Managing Director of Lupin, expressed excitement about the partnership, stating it reinforces their commitment to meeting patients' unmet needs in India and enhancing their gastroenterology portfolio.

Related News

News Thumbnail
Company

L&T Partners with PS Technology to Revolutionise Railways

6 mins read. August 2, 2024 at 12:45 PM

News Thumbnail
Company

Jindal Saw Q1 FY24 PAT Rises 67% to Rs 441 Cr

4 mins read. August 2, 2024 at 12:41 PM

News Thumbnail
Company

Pfizer Q1 FY25 PAT Zooms 61% to Rs 151 Cr

4 mins read. August 2, 2024 at 12:36 PM

News Thumbnail
Company

NBCC Arm Gets Two Construction Projects Worth Rs 443.61 Cr

4 mins read. August 2, 2024 at 12:33 PM

Related Blogs

Stock chartDemat Account

Biggest Winners and Losers in MSCI: Key Movers in Global Indices 2025

0 people read

3 mins read . Aug 20, 2025

Stock chartMutual Fund

What MF Big Boys Bought and Sold – Top Mutual Fund Stock Activity in 2025

0 people read

8 mins read . Aug 18, 2025

Download app

Access BlinkX
everywhere
across device

Join the Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions